Argos Therapeutics   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Durham NC United States (1997)
Status: Acquired by Genexine, Inc. (2019)

Organization Overview

First Clinical Trial
2004
NCT00087984
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2014

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 3 Trials (1)

autologous dendritic cells (4 trials)

Drugs in Phase 2 Trials (3)

ags-004 (4 trials)

mb-002 (1 trial)

sunitinib (sutent) (1 trial)

Drugs in Phase 1 Trials (1)

ags-009 (1 trial)

Drugs in Other Trials (1)

ags-006 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acquired Immunodeficiency Syndrome (Phase 2)

Carcinoma (Phase 3)

Carcinoma, Renal Cell (Phase 3)

HIV Infections (Phase 2)

HIV Seropositivity (Phase 2)

Immunologic Deficiency Syndromes (Phase 2)

Inflammation (Phase 1)

Lupus Erythematosus, Systemic (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 11
  • # of Trial APIs: 6